Ad is loading...
MENU

IDYA Stock IDEAYA Biosciences (IDYA, $26.64) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 15, 2024

A.I.dvisor
at Tickeron.com
Loading...
IDYA - IDEAYA Biosciences
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $26.64
Daily change: -$2.83 (-9.6%)
Daily volume: 1.2M
Industry: Biotechnology
This is a Bearish indicator signaling IDYA's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 48 similar cases where IDYA's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

Momentum Indicator for IDYA turns negative, indicating new downward trend

IDYA saw its Momentum Indicator move below the 0 level on November 15, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 106 similar instances where the indicator turned negative. In of the 106 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for IDYA turned negative on November 15, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDYA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for IDYA entered a downward trend on November 07, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IDYA's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDYA advanced for three days, in of 308 cases, the price rose further within the following month. The odds of a continued upward trend are .

IDYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.948) is normal, around the industry mean (13.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.241). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.798). IDYA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (526.316) is also within normal values, averaging (221.024).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IDYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
IDYA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
7000 Shoreline Court
Phone
+1 650 443-6209
Employees
124
Web
https://www.ideayabio.com